Key Drivers
- Very high liquidity
- Heavy cash burn
- Financing reliance
AIAI Summary
ATAI has shifted from a speculative platform bet to a binary, execution‑driven investment where 2026 Phase‑3 starts and pivotal readouts (especially BPL‑003 and EMP‑01) will materially re‑rate the stock, while high cash burn and reliance on financing mean trial success or non‑dilutive partnerships are essential to prevent sharp dilution and valuation compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high liquidity
- •Heavy cash burn
- •Financing reliance
ATAI has a very strong liquidity and low leverage cushion ( ~$264.8M cash + investments vs $70.7M liabilities) but is burning >$100M/year with minimal revenue and heavy reliance on financing to fund operations.
Price Behavior
Key Price Behavior Insights:
- •Below last-month average
- •Near defined support
- •Volatile recent swings
Short-term mildly bearish: price at $3.49 is ~7.7% below last month's average of $3.78 and sits near support at $3.39, with $4.14–$4.37 area as key resistance to confirm any reversal.
Sharp rise to $4.37 (2026-02-24) followed by a fall toward $3.39 shows elevated short-term volatility
Sentiment & News
Key News Insights:
- •Phase‑2 efficacy
- •Phase‑3 alignment
- •Q2 pivotal start
AtaiBeckley reported positive Phase 2 signals for EMP‑01 and BPL‑003, secured FDA alignment on BPL‑003 Phase 3 plans, and confirmed Q2‑2026 pivotal starts alongside financial/corporate updates.
The updates materially de‑risk near‑term clinical timelines and should support upside sentiment ahead of the planned Phase 3 initiations
Similar Companies in Healthcare
Other companies in the same sector with AI ratings